Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
OCUL
Stock Latest News
The Fly
Ocular Therapeutix enrolls first patient in Axpali trial
7h ago
OCUL
Premium
The Fly
Ocular Therapeutix reports additional Axpaxli trial data
16d ago
OCUL
Premium
The Fly
Ocular Therapeutix price target raised to $27 from $24 at BofA
2M ago
OCUL
Premium
Ratings
OCUL: SOL-1 Phase 3 Data, Regulatory Strategy, and Durability Advantages Underpin Reaffirmed Buy Rating and $27 Target
2M ago
OCUL
Premium
The Fly
Ocular Therapeutix price target raised to $28 from $21 at Clear Street
2M ago
OCUL
Premium
Ratings
Axpaxli’s Superior SOL-1 Phase 3 Data Support Buy Rating and Constructive Outlook on Ocular Therapeutix
2M ago
OCUL
Premium
Ratings
OCUL: Strengthening Axpaxli Clinical Profile and Manageable Safety Support Buy Rating in Neovascular AMD
2M ago
OCUL
Premium
Company Announcements
Ocular Therapeutix Highlights Phase 3 AXPAXLI Trial Progress
2M ago
8K
OCUL
Premium
The Fly
Ocular Therapeutix selloff brings attractive entry point, says Citizens
2M ago
OCUL
Premium
The Fly
Midday Fly By: Warner Bros. reopens Paramount talks
2M ago
DG
DHR
Premium
Ratings
Ocular Therapeutix: SOL-1 Data Validate Axpaxli and Overdone Sell-Off Supports Buy Rating
2M ago
OCUL
Premium
The Fly
Jefferies stays constructive on Ocular Therapeutix despite SOL-1 selloff
2M ago
OCUL
Premium
The Fly
Ocular Therapeutix announces SOL-1 Phase 3 of Axpaxli met primary endpoint
2M ago
OCUL
Premium
Company Announcements
Regulatory Turbulence Threatens Ocular Therapeutix: FDA Disruptions and Global Delays Raise Approval and Funding Risks
3M ago
OCUL
Premium
The Fly
Ocular Therapeutix reports Q4 EPS (29c), consensus (34c)
3M ago
OCUL
Premium
Company Announcements
Ocular Therapeutix appoints Jason Robins interim CFO
3M ago
8K
OCUL
Premium
The Fly
Ocular Therapeutix appoints Robinson as Global Chief Commercial Officer
3M ago
MRK
OCUL
Premium
The Fly
Unusually active option classes on open January 16th
3M ago
LAC
LDI
Premium
The Fly
Sanofi prepping higher bid for Ocular Therapeutix, IBD reports
3M ago
SNY
OCUL
Premium
The Fly
Ocular Therapeutix rises 11.7%
3M ago
OCUL
Premium
Company Announcements
Ocular Therapeutix Enters Quiet Period Ahead of SOL-1 Milestone
4M ago
8K
OCUL
Premium
Ratings
Strong Buy Rating for Ocular Therapeutix Backed by Enhanced Regulatory Pathway and Promising Axpaxli Trial Data
4M ago
OCUL
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
